Laino, Andressa S
Woods, David https://orcid.org/0000-0002-6328-8107
Vassallo, Melinda
Qian, Xiaozhong
Tang, Hao
Wind-Rotolo, Megan
Weber, Jeffrey
Clinical trials referenced in this document:
Documents that mention this clinical trial
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
https://doi.org/10.1136/jitc-2019-000234
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
https://doi.org/10.1136/jitc-2022-sitc2022.0608
Documents that mention this clinical trial
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
https://doi.org/10.1016/j.ejca.2013.06.027
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
https://doi.org/10.1016/j.clinthera.2015.02.018
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
https://doi.org/10.1136/jitc-2022-sitc2022.0608
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
https://doi.org/10.1200/jco.24.00400
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.
https://doi.org/10.1200/jco.2023.41.16_suppl.9542
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
https://doi.org/10.1016/j.ejca.2013.06.027
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
https://doi.org/10.1016/j.clinthera.2015.02.018
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
https://doi.org/10.1136/jitc-2023-008372
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
https://doi.org/10.1136/jitc-2021-003743
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers
https://doi.org/10.1136/jitc-2025-013252
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
https://doi.org/10.1136/jitc-2022-sitc2022.0608
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
https://doi.org/10.1200/jco.24.00400
387 The utility of AI-powered spatial classification of intratumoral CD8+ immune-cell distribution in predicting overall survival in patients with melanoma as part of the checkMate 067 clinical trial
https://doi.org/10.1136/jitc-2021-sitc2021.387
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
https://doi.org/10.1136/rmdopen-2022-002612
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
https://doi.org/10.1136/jitc-2019-000234
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
https://doi.org/10.1136/jitc-2020-000878
Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
https://doi.org/10.1136/jitc-2020-001996
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007310
Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.9538
Circulating tumour cell clusters: isolation, biological significance and therapeutic implications
https://doi.org/10.1136/bmjonc-2024-000437
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749).
https://doi.org/10.1200/jco.2024.42.23_suppl.222
816 Selective immune suppression using interleukin-6 blockade in immune related adverse events
https://doi.org/10.1136/jitc-2021-sitc2021.816
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
https://doi.org/10.1136/jitc-2020-001145
Funding for this research was provided by:
National Cancer Institute (K99/R00 CA230201-01)
National Cancer Institute (R01 CA175732-01)